Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study shows the benefits of pallidal DBS for the dystonia of PKAN patients.
|
15852393 |
2005 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The present study confirms the effectiveness of pallidal DBS in a new family with hereditary primary segmental and generalized dystonia.
|
19890997 |
2009 |
Dystonia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Some of the rarer types of dystonia that have also been treated with DBS are also described.
|
20083014 |
2009 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There was a significant improvement of dystonia with GPi-DBS (69 % improvement in Burke-Fahn-Marsden score, p < 0.0001).
|
24178706 |
2014 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinically, no generalization of dystonia was observed after onset and DBS lead to an excellent motor outcome in two cases.
|
26725140 |
2016 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
As the course of disease duration as well as the age at operation seem to correlate with DBS outcome in patients with dystonia, DBS at an early stage of development might be beneficial for some of these patients.
|
27289260 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
GPi-DBS should be considered to ameliorate the invalidating dystonia in these patients.
|
27862284 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
DBS effects on dystonia severity were variable but overall marginally effective, with a mean improvement of 7.9% (p = 0.39) at 1-year follow-up and 16.7% (p = 0.46) at last follow-up (mean 47.3 ± 19.9 months after surgery).
|
27743838 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To assess safety and tolerability of square biphasic DBS in dystonia patients.
|
28195407 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
GPi DBS is an effective and safe treatment in most patients with dystonia.
|
28972096 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results showed that bilateral GPi DBS in craniocervical dystonia is effective and safe.
|
29246604 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We here investigated causes of insufficient response to GPi-DBS in isolated dystonia in a cross-sectional study.
|
28690015 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pallidal DBS for dystonia in the age of personalized medicine.
|
28964627 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We describe lessons learnt from available dystonia studies and discuss/propose ways to measure DBS and other dystonia-related intervention outcomes.
|
27707656 |
2017 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Fifty-four subjects with dystonia and DBS for more than 5 years were contacted via social media and were offered to complete a quality-of-life survey comparing current-day life and life prior to DBS.
|
30153389 |
2018 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
All these results support the multilevel impact of effective DBS on the motor networks in dystonia and suggest potential biomarkers of responsiveness to this treatment.
|
30464181 |
2018 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
DBS has been trialed to treat related movement disorders, particularly dystonia.
|
30633810 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Interestingly, DBS for PD can cause dystonia such as blepharospasm and bilateral pallidal DBS for dystonia can result in features of parkinsonism.
|
31078682 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pallidal deep-brain stimulation of the internal globus pallidus (GPi-DBS) is an effective treatment for dystonia.
|
30623266 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We aimed to assess whether the thalamic ventral intermediate nucleus (Vim) might be an alternative DBS target in dystonia-choreoathetosis.
|
30718219 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Peak low frequency IMC functioned as biomarker for GPi-DBS efficacy, and partly correlated with dystonia severity.
|
31207566 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To objectively investigate the impact of GPi-DBS on patients with dystonia on speech fluency, intelligibility, and key aspects of hyperkinetic and hypokinetic dysarthria.
|
29576500 |
2019 |
Dystonia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A dramatic and long-lasting response to DBS is characteristic of DYT-KMT2B dystonia.
|
31216378 |
2019 |